Original Article

Relationship between right and left ventricular function in candidates for implantable cardioverter defibrillator with low left ventricular ejection fraction

Laura Jimenez-Juan, MDa,b,*, Gauri R. Karur, MDc, Kim A. Connelly, MD, PhDb,c,d, Djeven Deva, MDc, Raymond T. Yan, MDb, Rachel M. Wald, MDb,f, Sheldon Singh, MDd,e, General Leung, PhDb,e, Anastasia Oikonomou, MD, PhDbc, Paul Dorian, MDc, Paul Angaran, MDc, Andrew T. Yan, MDc

*Department of Medical Imaging, Sunnybrook Health Sciences Centre, Toronto ON, Canada
†University of Toronto, Toronto, ON, Canada
‡Division of Cardiology, St Michael’s Hospital, Toronto, ON, Canada
§Division of Cardiology, Schulich Heart Centre and Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
©Department of Medical Imaging, St. Michael’s Hospital, Toronto, ON, Canada
¶Division of Cardiology and Medical Imaging, University Health Network, Toronto, ON, Canada

A B S T R A C T

Background: Indications for the primary prevention of sudden death using an implantable cardioverter defibrillator (ICD) are based predominantly on left ventricular ejection fraction (LVEF). However, right ventricular ejection fraction (RVEF) is also a known prognostic factor in a variety of structural heart diseases that predispose to sudden cardiac death. We sought to investigate the relationship between right and left ventricular parameters (function and volume) measured by cardiovascular magnetic resonance (CMR) among a broad spectrum of patients considered for an ICD.

Methods: In this retrospective, single tertiary-care center study, consecutive patients considered for ICD implantation who were referred for LVEF assessment by CMR were included. Right and left ventricular function and volumes were measured.

Results: In total, 102 patients (age 62 ± 14 years; 23% women) had a mean LVEF of 28 ± 11% and RVEF of 44 ± 12%. The left ventricular and right ventricular end diastolic volume index was 140 ± 42 ml/m² and 81 ± 27 ml/m², respectively. Eighty-six (84%) patients had a LVEF < 35%, and 63 (62%) patients had right ventricular systolic dysfunction. Although there was a significant and moderate correlation between LVEF and RVEF (r = 0.40, p < 0.001), 32 of 86 patients (37%) with LVEF < 35% had preserved RVEF, while 9 of 16 patients (56%) with LVEF ≥ 35% had right ventricular systolic dysfunction (Kappa = 0.041).

Conclusions: Among patients being considered for an ICD, there is a positive but moderate correlation between LVEF and RVEF. A considerable proportion of patients who qualify for an ICD based on low LVEF have preserved RVEF, and vice versa.

© 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

An implantable cardioverter defibrillator (ICD) is an effective treatment to reduce mortality in patients with advanced heart failure with left ventricular ejection fraction (LVEF) < 30% [1–3]. The decision to implant an ICD for primary prevention is complex, but largely depends on a LVEF < 30–35%, which is a major inclusion criterion in the landmark ICD trials [2–8].

Prediction of ICD treatment benefit in individual patients remains difficult and a large proportion of patients with an ICD never receive an appropriate shock. Conversely, some patients with relatively preserved LVEF suffer sudden cardiac death. Therefore, additional and more refined risk assessments are needed to improve patient selection for ICD implantation [3].

Right ventricular ejection fraction (RVEF) is an independent predictor of survival in patients with heart failure [9–11]. Previous studies suggest that the RVEF may have a prognostic value in post-myocardial infarction patients [10–12], and a poor right ventricular...
function may be an independent predictor of life-threatening arrhythmia [12,13]. In addition, there are other conditions in which right ventricular systolic dysfunction (RVSD) may have an important prognostic value. For example, in patients with arrhythmogenic right ventricular dysplasia, RVSD is a major diagnostic criterion [13,14]. In patients with pulmonary arterial hypertension and congenital conditions such as tetralogy of Fallot, a poor RVEF is a predictor of poor outcome, and this affects patient management [14,15]. However, other ventricular parameters such as RVEF and ventricular volumes in patients receiving ICD have not been well studied.

Cardiovascular magnetic resonance imaging (CMR) is recognized as a versatile, safe, and reproducible technique, allowing for accurate structural and functional assessment of the heart. CMR is the gold standard for ejection fraction measurement [15–17]. Considering the technical limitations of other imaging modalities such as 2D echocardiography, this method is particularly useful to measure RVEF [13,16,17].

The purpose of this study is to assess the relationship between RVEF and LVEF, as measured by CMR in patients referred for ICD implantation. We also evaluated the relationship between LVEF, RVEF, and right and left ventricular volumes. This is clinically relevant because if there is no strong correlation between left ventricular (LV) and right ventricular (RV) parameters, there is a potential for the RV assessment to offer an incremental value in ICD stratification.

2. Materials and methods

2.1. Study design and patient population

This retrospective, single-center study was approved by the institutional research ethics board. We included consecutive patients considered for ICD implantation (primary prevention) who underwent CMR between March 2007 and October 2009, identified from a clinical database. Patients with incomplete imaging datasets were excluded, but there were no other exclusion criteria so as to reflect a “real world” cohort of patients.

2.2. Cardiovascular magnetic resonance imaging

CMR studies were performed on a commercially available 1.5 T whole body scanner (Achieva, Philips, Medical Systems, Best, Netherlands). The standard CMR protocol included ECG gated steady-state free precession imaging in short axis orientation, perpendicular to the left ventricular long axis. Ten to 12 contiguous slices were obtained during 10–20 s of breath holds (slice thickness 8 mm, with no inter-slice gap, in plane resolution 1.6 × 1.6 mm). Late gadolinium enhancement images were acquired approximately 10 minutes after intravenous administration of 0.1–0.2 mmol/kg of gadolinium (gadopentate dimeglumine) with the inversion time adjusted to optimally null the normal myocardium. All CMR data were obtained by a single experienced reader blinded to other clinical data, using a commercially available workstation (Extended Workstation, Philips Medical Systems). Measurement of right and left ventricular volumes (end-diastolic and end-systolic volumes), stroke volumes, and ejection fraction were obtained in short axis orientation, according to the standard criteria [13,18]. To assess inter-observer reliability, a second experienced CMR reader independently measured the RVEF in 20 randomly selected cases.

LVEF < 35%, which is a commonly used threshold for ICD implantation [2,18,19], was used as a cut-off value for moderate to severe LV dysfunction. We defined RVSD as abnormal RVEF < 47% for men or < 53% for women [2,19,20]. We defined dilated left ventricle as left ventricular end-diastolic indexed volume > 108 mL/m² (male) or 102 mL/m² (female) and dilated RV as right ventricular end-diastolic indexed volume > 126 mL/m² (male) or 118 mL/m² (female) [20].

We evaluated the presence of chronic right ventricular myocardial infarction in the late gadolinium enhancement images.

2.3. Statistical analysis

Continuous variables are expressed as mean ± standard deviation (for normally distributed data) and categorical variables as number and percentage. The relationship between continuous variables (RVEF and LVEF) was assessed by the non-parametric Spearman’s correlation coefficient (r). The chi-square test (or Fisher’s exact test, where appropriate) was used for comparisons of categorical variables. We used Cohen’s kappa statistic to measure the agreement between LV and RV dysfunction. The intra-class correlation coefficient (ICC) was calculated to assess inter-observer agreement. A p-value of 0.05 (2-tailed) was defined as statistically significant. Statistical analyses were performed using SPSS 20.0 (IBM Corp., Armonk, New York, USA).

3. Results

3.1. Baseline clinical characteristics

A total of 102 patients were identified, among whom 63 (62%) had RVSD and 39 (38%) had normal RVEF. The baseline clinical characteristics did not differ between patients who had RVSD and normal RVEF (Table 1). CMR data are summarized in Table 2. There was good inter-observer reliability in RVEF measurements between the 2 CMR readers (ICC = 0.80, p < 0.001).

3.2. Relationship between RV and LV systolic function

Fig. 1 is a scatterplot showing the relationship between the RVEF and LVEF. There was a positive but moderate correlation between LVEF and RVEF (r = 0.40, p < 0.001). Approximately half of patients had both an LVEF < 35% and RVSD (n = 54, 53%), but 32 of 86 patients (37%) with LVEF < 35% had preserved RVEF, while 9 of 16 patients (56%) with LVEF ≥ 35% had RVSD. Table 3 demonstrates the correlation between LVEF and RVEF values.

Table 1 Baseline clinical characteristics of the study population according to right ventricular function.

|                          | Total | RVEF < 47% (M) or < 53% (F) | RVEF ≥ 47% (M) or ≥ 53% (F) | p-value |
|--------------------------|-------|----------------------------|-----------------------------|---------|
| n                        | 102   | 63 (62%)                   | 39 (38%)                    |         |
| Age, years               |       |                            |                             |         |
|                         | 62 ± 14 | 62 ± 12                     | 62 ± 16                     | 0.64    |
| Gender (female)          | 23 (23%) | 17 (27%)                     | 33 (85%)                    | 0.25    |
| Hypertension             | 62 (61%) | 40 (63%)                     | 22 (56%)                    | 0.53    |
| Dyslipidemia             | 69 (68%) | 40 (53%)                     | 29 (74%)                    | 0.28    |
| History of smoking       | 49 (48%) | 27 (43%)                     | 22 (56%)                    | 0.98    |
| Current smoker           | 7 (7%)  | 6 (10%)                      | 1 (3%)                      |         |
| Diabetes                 | 41 (40%) | 25 (40%)                     | 16 (41%)                    | 1.00    |
| Prior MI                 | 61 (60 %) | 36 (37%)                     | 25 (64%)                    | 0.54    |
| LGE RCA territory        | 25 (24%) | 25 (100%)                    | 0                            |         |
| Prior heart failure      | 53 (52%) | 28 (44%)                     | 25 (64%)                    | 0.07    |
| Prior PCI                | 37 (36%) | 22 (35%)                     | 15 (40%)                    | 0.83    |
| Prior CABG               | 23 (23%) | 13 (21%)                     | 10 (26%)                    | 0.63    |

Data are presented as mean ± standard deviation or number and percentage. CABG, coronary artery bypass grafting; F, female; LGE, late gadolinium enhancement; M, male; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery; RVEF, right ventricular ejection fraction.
had a dilated RV (Table 4).

**Table 2**

Left and right ventricular volume and ejection fraction.

| Value                        | Mean ± SD |
|------------------------------|-----------|
| LVEDV, ml                    | 267 ± 85  |
| LVEDVi, ml/m²                | 140 ± 42  |
| LVESV, ml                    | 197 ± 80  |
| LVESVi, ml/m²                | 103 ± 40  |
| LVEF, %                      | 28 ± 11   |
| RVEDV, ml                    | 156 ± 56  |
| RVESV, ml                    | 81 ± 27   |
| RVESVi, ml/m²                | 47 ± 22   |
| RVEF, %                      | 44 ± 12   |

LVEDV, left ventricular end-diastolic volume; LVEDVi, left ventricular end-diastolic indexed volume; LVESV, left ventricular end-systolic volume; LVESVi, left ventricular end-systolic indexed volume; RVEDV, right ventricular end-diastolic volume; RVESV, right ventricular end-systolic volume; RVESVi, right ventricular end-systolic indexed volume; RVEF, right ventricular ejection fraction; RVESVi, right ventricular end-systolic indexed volume.

The majority had a normal RV size (Table 4). Among the 63 patients with RVSD, 35% had a normal RV size but a dilated left ventricle (Table 4). Among the 39 patients in whom LVESV could be assessed, 35% had a normal LV size but moderately to severely reduced LVEF [2,4,6,8,20]. This is also the main criterion in current evidence-based guidelines for ICD implantation [2,4,6,7,21]. However, there is increasing evidence of substantial variability and underutilization of ICD, as well as inappropriate shocks and implant complications [22]. Therefore, there is a need for more accurate risk stratification that enhances the selection of patients who will derive the greatest benefit from ICD therapy, with the ultimate goal to improve patient care and health outcomes in a cost-effective manner.

**Table 4**

| Relationship between RV and LV systolic function. |
|--------------------------------------------------|
| ![Image](image)                                  |

Fig. 1. Relationship between right and left ventricular function. Scatterplot demonstrates a positive but only moderate correlation between the right and the left ventricular ejection fraction (Spearman $r=0.40, p<0.001$). LVEF, left ventricular ejection fraction; RVEF, right ventricular ejection fraction.

**Table 3**

Relationship between LVEF and RVEF.

| RVEF ≥ 47% (M) or ≥ 53% (F) | RVEF < 47% (M) or < 53% (F) | Total |
|-----------------------------|-----------------------------|-------|
| LVEF ≥ 35%                  | 7                           | 9     | 16    |
| LVEF < 35%                  | 32                          | 54    | 86    |
| Total                       | 39                          | 63    | 102   |

F, female; LVEF, left ventricular ejection fraction; M, male; RVEF, right ventricular ejection fraction.

3.3. Relationship between RV and LV systolic function and volume

We examined the relationship of RVEF and LVEF with other ventricular parameters, including right and left end-diastolic ventricular indexed volumes. Among the 63 patients with RVSD, the majority had a normal RV size ($n=56, 88\%$) but a dilated left ventricle ($n=44, 70\%$). Of the 86 patients with LVEF < 35%, 14 (54%) patients had a normal LV volume, whereas 7 (8%) patients had a dilated RV (Table 4).

3.4. Chronic RV myocardial infarction

We evaluated the presence of chronic right myocardial infarction in the late gadolinium enhancement images. Twenty-five (24%) patients had positive late gadolinium enhancement in the RV consistent with chronic myocardial infarction in the RV territory. All these patients also had RVSD.

4. Discussion

In this single-center study, we observed a positive but only moderate correlation between RVEF and LVEF in patients considered for ICD implantation. More than half of the patients with LVEF < 35%–which is the most commonly accepted threshold value for ICD implantation—had also RVSD. The majority of patients with RVSD had a normal RV size and dilated LV, whereas the majority of patients with LVEF < 35% had a dilated LV but normal RV size. Since there is positive but only moderate correlation between RV and LV structural and functional parameters in patients referred for potential ICD implantation, RV assessment may offer valuable information for risk stratification of ICD candidates.

Since the largest ICD clinical trials included patients with a moderately to severely reduced LVEF [2,4,6,8,20], this is also the main criterion in current evidence-based guidelines for ICD implantation [2,4,6,7,21]. However, there is increasing evidence of substantial variability and underutilization of ICD, as well as inappropriate shocks and implant complications [22]. Therefore, there is a need for more accurate risk stratification that enhances the selection of patients who will derive the greatest benefit from ICD therapy, with the ultimate goal to improve patient care and health outcomes in a cost-effective manner.

RVSD is as an independent predictor of mortality in patients with heart failure and adverse outcomes after myocardial infarction [10,12,23]. In patients with idiopathic dilated cardiomyopathy, RVEF has also been shown to be an independent predictor of survival [12,24,25], and biventricular involvement represents a typical feature of this disease. In a case control study of 57 ICD patients, Malasana and colleagues identified a higher prevalence of RVSD in the group with ICD shocks than in those who did not have ICD shocks. However, this study included only a small number of patients, and the relationship between the LV and RV was not analyzed [13]. Our study, building on previous work, is the first to analyze the relationship between the LVEF and RVEF in a cohort with a wider range of LVEF values who were considered for ICD implantation. Tabereaux and colleagues demonstrated that
RVSD represents a strong predictor of lack of clinical response to cardiac resynchronization therapy (CRT) in patients with heart failure due to left ventricular dysfunction, and should be considered when prescribing CRT [26]. However, this remains unexplored in the ICD population. In arrhythmogenic right ventricular dysplasia [22], RVSD is a major diagnostic criterion, and ICD is an important therapeutic option; however, current guidelines do not contemplate the inclusion of morphologic or functional RV parameters in the decision of ICD implantation [14,27]. A multicenter study of patients with tetrology of Fallot [23,27] suggested the importance of ICD therapy in preventing sudden death in high-risk patients. In these patients, RV deterioration is an important prognostic indicator. Although in these specific diseases, the RV may be the origin of life-threatening arrhythmias, it is not known whether RV structural and functional parameters may afford additional guidance for ICD placement in the majority of patients who have LV dysfunction.

In our patient cohort, there was a positive but moderate correlation between RVEF and LVEF in patients being considered for ICD implantation. These results raise the potential value of RVEF in the risk stratification of patients being considered for ICD implantation, independent of the LVEF. It is important to note that, if there is a very strong correlation between RVEF and LVEF, then RVEF could not provide any additional prognostic value.

Our study follows previous efforts to investigate the use of CMR in patients considered for ICD implantation. Joshi and colleagues demonstrated the contribution of CMR in the risk stratification of patients receiving an ICD [28]. About 20% of patients considered for ICD implantation were reclassified when studied by CMR as compared with echocardiography. More recently, the extent and heterogeneity of the scar in late gadolinium CMR imaging may predict the outcome [29,30], and have been proposed as additional promising markers to stratify risk in ICD patients [31]. CMR provides more accurate and reproducible measurements of RV volumes and function as compared with 2D echo or nuclear imaging. Our study suggests that RVEF assessment might be another useful parameter in assessing risk stratification of ICD candidates.

The present study has a number of limitations. It is a retrospective, single-center study, which could limit its external validity, although the lack of strict inclusion and exclusion criteria enhances the generalizability of our findings. We did not have detailed clinical information that could help in the definition of the etiology of the RV dysfunction, so in our population, we cannot exclude any additional cause of RV dysfunction. Furthermore, outcome data were not available in this study. Therefore, long-term follow-up studies to evaluate the relationship between RV function and ICD outcomes are warranted, and may help further risk-stratify patients with RV dysfunction. This will be the focus of our future research efforts.

5. Conclusion

There is a positive but only moderate relationship between RVEF and LVEF in patients being considered for ICD implantation. A considerable proportion of patients who qualify for ICD based on low LVEF have preserved RVEF, and vice versa. Given its prognostic value, RVEF assessment by CMR may have the potential to refine risk stratification beyond LVEF. Our findings support the need for long-term studies to determine whether RVEF independently predicts ICD benefit and should be incorporated into ICD management decisions.

Disclosures

None.

Funding

This research received no grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of interest

All authors declare no conflict of interest related to this study.

References

[1] Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473–82.
[2] Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225–37.
[3] Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med 2008;359:2245–53.
[4] Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997;337:1569–75.
[5] A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. N Engl J Med 337 (1997), pp. 1576–83.
[6] Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882–90.
[7] Connolly SJ, Gent M, Roberts RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297–302.
[8] Moss AJ, Zareba W, Hall WJ, et al. Multicenter automatic defibrillator implantation trial II investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877–83.
[9] Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Protected right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. JACC 1995;25:1143–53.
[10] de Groote P, Millaire A, Foucher-Hossein C, et al. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. JACC 1998;32:948–54.
[11] Lietz K, Long JW, Klouy AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007;116:497–505.
[12] Lemos E, Ganz P, Rebarber R, et al. Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction. J Am Coll Cardiol 2007;49:855–62.
[13] Malasan A, Daccarett M, Ruppahally S, et al. High prevalence of right ventricular dysfunction in ICD patients with shocks: a potential new predictor in risk stratification. J Interv Card Electrophysiol 2011;31:165–9.
[14] Marcus FI, McKenna WJ, Sutherland DR, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010;121:1533–41.
[15] Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008;118:e714–833.
[16] Pennell DJ. Cardiovascular magnetic resonance. Circulation 2010;121:692–705.
[17] Lima JAC, Desai MY. Cardiovascular magnetic resonance imaging: current and emerging applications. J Am Coll Cardiol 2004;44:1164–71.
[18] Schulz-Menger J, Bluemke DA, Bremerich J, et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: society for cardiovascular magnetic resonance (SCMR) board of trustees task force on standardization and reporting of CMR-Multigrid Analysis (CMR-MAG) working group. J Cardiovasc Magn Reson 2013;15:35.
[19] Epstein AE, DiMarco JP, Ellenbogen KA, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices), American Association for Thoracic Surgery, Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008;117:e350–408.
[20] Hudsmith L, Petersen S, Francis J, Robson M, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free.
precession magnetic resonance imaging. J Cardiovasc Magn Reson 2005;7:775–82.

[21] Russo AM, Stainback RF, Bailey SR, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol 2013;61:1318–68.

[22] Kusumoto FM, Calkins H, Boehmer J, et al. Heart Rhythm Society, American College of Cardiology, American Heart Association. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. J Am Coll Cardiol 2014;64:1143–77.

[23] Khairy P, Harris L, Landsberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. Circulation 2008;117:363–70.

[24] Juillière Y, Barbier G, Feldmann L, et al. Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy. Eur Heart J 1997;18:276–80.

[25] La Vecchia L, Zanolla I, Varotto L, et al. Reduced right ventricular ejection fraction as a marker for idiopathic dilated cardiomyopathy compared with ischemic left ventricular dysfunction. Am Heart J 2001;142:381–9.

[26] Tabereaux PB, Doppalapudi H, Kay GN, et al. Limited response to cardiac resynchronization therapy in patients with concomitant right ventricular dysfunction. J Cardiovasc Electrophysiol 2010;21:431–5.

[27] Bhonsale A, James CA, Tichnell C, et al. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardio-myopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. JACC 2011;58:1485–96.

[28] Joshi SB, Connelly KA, Jimenez Juan L, et al. Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation. J Cardiovasc Magn Reson 2012;14:69.

[29] Yan AT. Characterization of the peri-infarct zone by contrast-enhanced cardiovascular magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation 2006;114:32–9.

[30] Schmidt A, Azevedo CF, Cheng A, et al. Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 2007;115:2006–14.

[31] Klem I, Weinsaft JW, Bahnon TD, et al. Assessment of myocardial scar improves risk stratification in patients evaluated for cardiac defibrillator implantation. JACC 2012;60:408–20.